| Year |
Citation |
Score |
| 2022 |
Ghosh A, Chan W, Younes N, Davis BR. A Dynamic Risk Model for Multitype Recurrent Events. American Journal of Epidemiology. PMID 36549905 DOI: 10.1093/aje/kwac213 |
0.685 |
|
| 2020 |
Ho CLB, Sanders S, Breslin M, Doust J, Reid CM, Davis BR, Simpson LM, Brouwers FP, Nelson MR. Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysis. Journal of Human Hypertension. PMID 32152453 DOI: 10.1038/S41371-020-0323-7 |
0.309 |
|
| 2019 |
Juraschek SP, Simpson LM, Davis BR, Beach JL, Ishak A, Mukamal KJ. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults. Hypertension (Dallas, Tex. : 1979). HYPERTENSIONAHA11913. PMID 31476905 DOI: 10.1161/Hypertensionaha.119.13445 |
0.344 |
|
| 2019 |
Johnson K, Oparil S, Davis BR, Tereshchenko LG. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. Journal of the American Heart Association. 8: e011961. PMID 30943832 DOI: 10.1161/JAHA.119.011961 |
0.32 |
|
| 2019 |
Bowling CB, Davis BR, Luciano A, Simpson LM, Sloane R, Pieper CF, Einhorn PT, Oparil S, Muntner P. Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT. Journal of Clinical Hypertension (Greenwich, Conn.). PMID 30864748 DOI: 10.1111/Jch.13515 |
0.32 |
|
| 2019 |
Kostis WJ, Sargsyan D, Mekkaoui C, Moreyra AE, Cabrera J, Cosgrove NM, Sedjro JE, Kostis JB, Cushman WC, Pantazopoulos JS, Pressel SL, Davis BR. Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. Journal of Human Hypertension. PMID 30804464 DOI: 10.1038/S41371-019-0180-4 |
0.313 |
|
| 2018 |
Haywood LJ, Davis BR, Piller LB, Simpson LM, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. Journal of the National Medical Association. 110: 343-351. PMID 30126559 DOI: 10.1016/J.Jnma.2017.07.003 |
0.705 |
|
| 2018 |
Barzilay JI, Davis BR, Ghosh A, Pressel SL, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT. Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes. Journal of Diabetes and Its Complications. PMID 30030011 DOI: 10.1016/J.Jdiacomp.2018.07.003 |
0.695 |
|
| 2018 |
Barzilay JI, Davis BR, Pressel SL, Ghosh A, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT. The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications. American Journal of Hypertension. PMID 29360915 DOI: 10.1093/Ajh/Hpx223 |
0.678 |
|
| 2017 |
Haywood LJ, Davis BR, Piller LB, Cushman WC, Cutler JA, Ford CE, Simpson LM, Ghosh A, Soliman EZ, Wright JT. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Journal of the National Medical Association. 109: 172-181. PMID 28987246 DOI: 10.1016/J.Jnma.2017.02.005 |
0.707 |
|
| 2017 |
Barzilay JI, Davis BR, Pressel SL, Ghosh A, Puttnam R, Margolis KL, Whelton PK. The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk. Current Cardiology Reports. 19: 76. PMID 28752275 DOI: 10.1007/S11886-017-0888-0 |
0.674 |
|
| 2016 |
Ernst ME, Davis BR, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, Cushman WC, Einhorn PT, Oparil S, Grimm RH. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of the American Society of Hypertension : Jash. 10: 930-938.e9. PMID 27938852 DOI: 10.1016/J.Jash.2016.10.010 |
0.679 |
|
| 2016 |
Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI. Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial. Jama Internal Medicine. PMID 27893045 DOI: 10.1001/Jamainternmed.2016.6821 |
0.695 |
|
| 2016 |
Dewland TA, Soliman EZ, Davis BR, Magnani JW, Yamal JM, Piller LB, Haywood LJ, Alonso A, Albert CM, Marcus GM. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. Jama Internal Medicine. PMID 27367818 DOI: 10.1001/Jamainternmed.2016.2502 |
0.305 |
|
| 2016 |
Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P. Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 26912544 DOI: 10.2215/Cjn.04660415 |
0.315 |
|
| 2015 |
Alderman MH, Davis BR, Piller LB, Ford CE, Baraniuk MS, Pressel SL, Assadi MA, Einhorn PT, Haywood LJ, Ilamathi E, Oparil S, Retta TM. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). The American Journal of Cardiology. PMID 26589819 DOI: 10.1016/j.amjcard.2015.10.012 |
0.353 |
|
| 2014 |
Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. Journal of the American Society of Hypertension : Jash. 8: 808-19. PMID 25455006 DOI: 10.1016/j.jash.2014.08.003 |
0.309 |
|
| 2014 |
Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 64: 1012-21. PMID 25259745 DOI: 10.1161/Hypertensionaha.114.03850 |
0.356 |
|
| 2013 |
Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, et al. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Journal of Clinical Hypertension (Greenwich, Conn.). 15: 542-54. PMID 23889716 DOI: 10.1111/Jch.12139 |
0.355 |
|
| 2013 |
Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension. 61: 977-86. PMID 23529173 DOI: 10.1161/HYPERTENSIONAHA.111.00213 |
0.317 |
|
| 2013 |
Lynch AI, Irvin MR, Boerwinkle E, Davis BR, Vaughan LK, Ford CE, Aissani B, Eckfeldt JH, Arnett DK, Shrestha S. RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. The Pharmacogenomics Journal. 13: 330-4. PMID 22664477 DOI: 10.1038/Tpj.2012.22 |
0.308 |
|
| 2012 |
Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT, Barzilay JI, Brown CD, Colon PJ, Fine LJ, Grimm RH, Gupta AK, Baimbridge C, Haywood LJ, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clinical Journal of the American Society of Nephrology : Cjasn. 7: 989-1002. PMID 22490878 DOI: 10.2215/CJN.07800811 |
0.311 |
|
| 2012 |
Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 59: 926-33. PMID 22431578 DOI: 10.1161/HYPERTENSIONAHA.111.180554 |
0.35 |
|
| 2012 |
Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, Oparil S, Probstfield JL, Whelton PK, Wright JT, Alderman MH, Basile JN, Black HR, Grimm RH, Hamilton BP, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension (Greenwich, Conn.). 14: 20-31. PMID 22235820 DOI: 10.1111/J.1751-7176.2011.00568.X |
0.384 |
|
| 2011 |
Piller LB, Baraniuk S, Simpson LM, Cushman WC, Massie BM, Einhorn PT, Oparil S, Ford CE, Graumlich JF, Dart RA, Parish DC, Retta TM, Cuyjet AB, Jafri SZ, Furberg CD, ... ... Davis BR, et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 124: 1811-8. PMID 21969009 DOI: 10.1161/Circulationaha.110.012575 |
0.325 |
|
| 2010 |
Einhorn PT, Davis BR, Wright JT, Rahman M, Whelton PK, Pressel SL. ALLHAT: still providing correct answers after 7 years. Current Opinion in Cardiology. 25: 355-65. PMID 20520537 DOI: 10.1097/HCO.0b013e32833a8828 |
0.306 |
|
| 2009 |
Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Journal of the American College of Cardiology. 54: 2023-31. PMID 19926008 DOI: 10.1016/j.jacc.2009.08.020 |
0.337 |
|
| 2009 |
Wright JT, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Archives of Internal Medicine. 169: 832-42. PMID 19433694 DOI: 10.1001/archinternmed.2009.60 |
0.326 |
|
| 2008 |
Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation. 117: 163-168. PMID 18172029 DOI: 10.1161/Circulationaha.107.727545 |
0.345 |
|
| 2007 |
Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. The Pharmacogenomics Journal. 7: 112-22. PMID 16702981 DOI: 10.1038/Sj.Tpj.6500395 |
0.307 |
|
| 2006 |
Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 48: 374-84. PMID 16864749 DOI: 10.1161/01.Hyp.0000231662.77359.De |
0.349 |
|
| 2006 |
Davis BR, Cutler JA. Data monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Early termination of the doxazosin treatment arm Data Monitoring in Clinical Trials: a Case Studies Approach. 248-259. DOI: 10.1007/0-387-30107-0_23 |
0.319 |
|
| 2005 |
Rahman M, Pressel S, Davis B. Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs. a Diuretic. A Report From the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Acc Current Journal Review. 14: 15-16. DOI: 10.1016/j.accreview.2005.08.026 |
0.304 |
|
| 2004 |
Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Archives of Internal Medicine. 164: 969-76. PMID 15136305 DOI: 10.1001/Archinte.164.9.969 |
0.333 |
|
| 2002 |
Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, Cushman W, Grimm R, Haywood LJ, Leenen F, Oparil S, Probstfield J, Whelton P, Nwachuku C, Gordon D, et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) Journal of the American Medical Association. 288: 2998-3007. PMID 12479764 DOI: 10.1001/jama.288.23.2998 |
0.368 |
|
| 2002 |
Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, Cushman W, Grimm R, Haywood LJ, Leenen F, Oparil S, Probstfield J, Whelton P, Nwachuku C, Gordon D, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) Journal of the American Medical Association. 288: 2981-2997. PMID 12479763 DOI: 10.1001/Jama.288.23.2981 |
0.308 |
|
| 2002 |
Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Williamson JD, Leenen FH, Einhorn PT, Randall OS, Golden JS, Haywood LJ. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Current Controlled Trials in Cardiovascular Medicine. 3: 10. PMID 12459039 DOI: 10.1186/1468-6708-3-10 |
0.315 |
|
| 2002 |
Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Annals of Internal Medicine. 137: 313-20. PMID 12204014 DOI: 10.7326/0003-4819-137-5_Part_1-200209030-00006 |
0.303 |
|
| 2001 |
Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Nwachuku C, Furberg CD. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Controlled Clinical Trials. 22: 29-41. PMID 11165421 DOI: 10.1016/S0197-2456(00)00109-4 |
0.309 |
|
| 1996 |
Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J. Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. Circulation. 94: 26-34. PMID 8964114 DOI: 10.1161/01.CIR.94.1.26 |
0.301 |
|
| 1996 |
Whelton PK, Williamson JD, Louis GT, Davis BR, Cutler JA. Experimental approaches to determining the choice of first-step therapy for patients with hypertension Clinical and Experimental Hypertension. 18: 569-579. PMID 8743044 DOI: 10.3109/10641969609088986 |
0.302 |
|
| 1996 |
Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. American Journal of Hypertension. 9: 342-60. PMID 8722437 DOI: 10.1016/0895-7061(96)00037-4 |
0.335 |
|
| 1994 |
Moyé LA, Davis BR, Hawkins CM, Probstfield JL. Conclusions and implications of the systolic hypertension in the elderly program. Clinical and Experimental Hypertension (New York, N.Y. : 1993). 15: 911-24. PMID 8268898 DOI: 10.3109/10641969309037081 |
0.322 |
|
| 1990 |
Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, Zimbaldi N, Hawkins CM. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Annals of Internal Medicine. 112: 89-95. PMID 1967210 DOI: 10.7326/0003-4819-112-2-89 |
0.306 |
|
| Show low-probability matches. |